Profiles of low-molecular proteome spectrum obtained through SELDI-TOF mass spectrometry in the sera of patients with metastatic malignant melanoma: Pilot study;Profily nízkomolekulárního proteomového spektra získané pomocí hmotnostní spektrometrie SELDI-TOF v sérech pacientů s diseminovaným maligním melanomem: Pilotní studie

Klinicka Onkologie

Volumn 22, Issue 5, 2009, Pages 228-232

  Lakomý, Radek ^a   Greplova K ^b   Pilny R ^b   Budinska E ^c   Valik D ^b   Poprach, A ^a   Nemecek R ^a   Vyzula, R ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b Masarykuv Onkologický Ústav ^*  (Czech Republic)

^c MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Biomarkers; Proteomic; SELDI TOF MS

Indexed keywords

BIOLOGICAL MARKER; PROTEOME;

ADULT; AGED; ARTICLE; CHEMOSENSITIVITY; CLINICAL ARTICLE; HUMAN; MELANOMA; METASTASIS; MOLECULAR WEIGHT; PILOT STUDY; SENSITIVITY AND SPECIFICITY; SERUM; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; BLOOD; DRUG RESISTANCE; FEMALE; MALE; MASS SPECTROMETRY; MIDDLE AGED; PATHOLOGY; SKIN TUMOR;

ADULT; AGED; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; PROTEOME; SKIN NEOPLASMS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 73349112908     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Pilný R, Michalová E, Brožková K et al. Příprava biologického materiálu pro metodu SELDI TOF MS. Brno: Edukační sborník XXXI. Brněnské onkologické dny 2007:360.
2. Wilson LL, Tran L, Morton DL. Detection of differentially expressed proteins in early-stage melanoma patients using SELDI-TOF mass spectrometry. Ann NY Acad Sci 2004,158:40-50.
3. Helanová S, Vyzula R, Žaloudík J et al. Technologie ciphergen - nová perspektiva v proteomice. Klinická ontologie 2004;17(5):157-161.
4. Liotta LA, Petricoin EF. General keynote: proteomic patterns in sera serve as biomarkers of ovarian cancer. Gynecol Oncol 2003;88(1 Pt 2):S25-S28. Discussion S37-S42.
5. Mian S, Ugurel S, Parkinson E. Serum Proteomic Fingerprinting Discriminates Between Clinical Stages and Predicts Disease Progression in Melanoma Patients. J Clin Oncol 2005;23:5088-5093.
6. Litvak A, Gupta R, Yee R. Endogenous Immune Response to Early and Intermediate-Stage Melanoma Is Correlated with Outcomes and Is Independent of Locoregional Relapse and Standard Prognostic Factors. J Am Coll Surg 2004;198:27-35.
7. Ding Y, Prieto V, Zhang R Nuclear Expression of the Anti-apoptotic Protein Survivin in Malignant Melanoma. Cancer 2006;106:1123-1129.
8. Geilen Ch, Georgieva J, Milling A. Malignant Melanoma - Markers for Progression and Prognosis in Malignant Melanoma, Front Radiat Ther Oncol. Basel: Karger 2006;39:120-126.
9. Cešková P, Brožková K, Hernychová L et al. Hmotnostní spektrometrie v kvantitativní a diagnostické proteomice: možnosti a limitace. Chem listy 2006;100(11):974-979.
10. Brožková K, Knofličková D, Hernychová L et al. Identifikace potenciálních biomarkerů karcinomu prsu metodou SELDI-TOF-MS. Klin onkol 2007;20(6):377-383.
11. Pilny R, Bouchai P, Borilova S et al. Surface-Enhanced Laser Desorption Ionization/Time-of-Flight Mass Spectrometry Reveals Significant Artifacts in Serum Obtained from Clot Activator-Containing Collection Devices. Clin Chem 2006;52(11):2115-2116.
12. Dušek L, Mužík J, Kubásek M et al. Česky̌ národni webovy̌ portál epidemiologie nádoru̇ [online]. Masarykova univerzita. Přístup z 2. 2. 2008. http://www.svod.cz. Verze 7.0.
13. Tusher VG, Tibshirani R et al. Significance analysis of microarrays applied to the ionizing radiation response. Proc NaH Aca Sci USA 2001;98(9):5116-5121.